BioSpace News Archive

TransCode Therapeutics, Inc., the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, announced that it has received written authorization from the U.S. Food and Drug Administration that it may proceed with its First-in-Human Phase 0 clinical trial.

Procaps Group, S.A., a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it will present at the 2023 J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:00 am PST.

Amyris, Inc. announced that it has entered into a definitive purchase agreement for the purchase and sale of 20,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 15,000,000 shares of common stock in a registered direct offering.

ALR Technologies SG Ltd., the diabetes management company, announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM.

Acer Therapeutics Inc. announced that The Nasdaq Stock Market LLC has formally notified Acer that the company has regained compliance with the $35 million market value of listed securities requirement, and otherwise satisfies all other criteria necessary, for continued listing on The Nasdaq Capital Market.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2022.

Neogen Corporation announced that the Company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023.

Hoth Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted an Investigational New Drug application for the company’s HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor inhibitor therapy.

Outlook Therapeutics, Inc. announced its financial results for its fiscal year ended September 30, 2022, and provided recent corporate highlights.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office.